FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895910368> ?p ?o ?g. }

• W2895910368 endingPage "1359" @default.
• W2895910368 startingPage "1350" @default.
• W2895910368 abstract "Background Global roll-out of rapid molecular assays is revolutionising the diagnosis of rifampicin resistance, predictive of multidrug-resistance, in tuberculosis. However, 30% of the multidrug-resistant (MDR) strains in an eSwatini study harboured the Ile491Phe mutation in the rpoB gene, which is associated with poor rifampicin-based treatment outcomes but is missed by commercial molecular assays or scored as susceptible by phenotypic drug-susceptibility testing deployed in South Africa. We evaluated the presence of Ile491Phe among South African tuberculosis isolates reported as isoniazid-monoresistant according to current national testing algorithms. Methods We screened records of 37 644 Mycobacterium tuberculosis positive cultures from four South African provinces, diagnosed at the National Health Laboratory Service–Dr George Mukhari Tertiary Laboratory, to identify isolates with rifampicin sensitivity and isoniazid resistance according to Xpert MTB/RIF, GenoType MTBDRplus, and BACTEC MGIT 960. Of 1823 isolates that met these criteria, 277 were randomly selected and screened for Ile491Phe with multiplex allele-specific PCR and Sanger sequencing of rpoB. Ile491Phe-positive strains (as well as 17 Ile491Phe-bearing isolates from the eSwatini study) were then tested by Deeplex-MycTB deep sequencing and whole-genome sequencing to evaluate their patterns of extensive resistance, transmission, and evolution. Findings Ile491Phe was identified in 37 (15%) of 249 samples with valid multiplex allele-specific PCR and sequencing results, thus reclassifying them as MDR. All 37 isolates were additionally identified as genotypically resistant to all first-line drugs by Deeplex-MycTB. Six of the South African isolates harboured four distinct mutations potentially associated with decreased bedaquiline sensitivity. Consistent with Deeplex-MycTB genotypic profiles, whole-genome sequencing revealed concurrent silent spread in South Africa of a MDR tuberculosis strain lineage extending from the eSwatini outbreak and at least another independently emerged Ile491Phe-bearing lineage. Whole-genome sequencing further suggested acquisition of mechanisms compensating for the Ile491Phe fitness cost, and of additional bedaquiline resistance following the introduction of this drug in South Africa. Interpretation A substantial number of MDR tuberculosis cases harbouring the Ile491Phe mutation in the rpoB gene in South Africa are missed by current diagnostic strategies, resulting in ineffective first-line treatment, continued amplification of drug resistance, and concurrent silent spread in the community. Funding VLIR-UOS, National Research Foundation (South Africa), and INNOVIRIS. Global roll-out of rapid molecular assays is revolutionising the diagnosis of rifampicin resistance, predictive of multidrug-resistance, in tuberculosis. However, 30% of the multidrug-resistant (MDR) strains in an eSwatini study harboured the Ile491Phe mutation in the rpoB gene, which is associated with poor rifampicin-based treatment outcomes but is missed by commercial molecular assays or scored as susceptible by phenotypic drug-susceptibility testing deployed in South Africa. We evaluated the presence of Ile491Phe among South African tuberculosis isolates reported as isoniazid-monoresistant according to current national testing algorithms. We screened records of 37 644 Mycobacterium tuberculosis positive cultures from four South African provinces, diagnosed at the National Health Laboratory Service–Dr George Mukhari Tertiary Laboratory, to identify isolates with rifampicin sensitivity and isoniazid resistance according to Xpert MTB/RIF, GenoType MTBDRplus, and BACTEC MGIT 960. Of 1823 isolates that met these criteria, 277 were randomly selected and screened for Ile491Phe with multiplex allele-specific PCR and Sanger sequencing of rpoB. Ile491Phe-positive strains (as well as 17 Ile491Phe-bearing isolates from the eSwatini study) were then tested by Deeplex-MycTB deep sequencing and whole-genome sequencing to evaluate their patterns of extensive resistance, transmission, and evolution. Ile491Phe was identified in 37 (15%) of 249 samples with valid multiplex allele-specific PCR and sequencing results, thus reclassifying them as MDR. All 37 isolates were additionally identified as genotypically resistant to all first-line drugs by Deeplex-MycTB. Six of the South African isolates harboured four distinct mutations potentially associated with decreased bedaquiline sensitivity. Consistent with Deeplex-MycTB genotypic profiles, whole-genome sequencing revealed concurrent silent spread in South Africa of a MDR tuberculosis strain lineage extending from the eSwatini outbreak and at least another independently emerged Ile491Phe-bearing lineage. Whole-genome sequencing further suggested acquisition of mechanisms compensating for the Ile491Phe fitness cost, and of additional bedaquiline resistance following the introduction of this drug in South Africa. A substantial number of MDR tuberculosis cases harbouring the Ile491Phe mutation in the rpoB gene in South Africa are missed by current diagnostic strategies, resulting in ineffective first-line treatment, continued amplification of drug resistance, and concurrent silent spread in the community." @default.
• W2895910368 created "2018-10-26" @default.
• W2895910368 creator A5002144784 @default.
• W2895910368 creator A5003579713 @default.
• W2895910368 creator A5004943027 @default.
• W2895910368 creator A5006354562 @default.
• W2895910368 creator A5006714387 @default.
• W2895910368 creator A5010157321 @default.
• W2895910368 creator A5014425130 @default.
• W2895910368 creator A5035684618 @default.
• W2895910368 creator A5044411310 @default.
• W2895910368 creator A5050887592 @default.
• W2895910368 creator A5054000066 @default.
• W2895910368 creator A5054459990 @default.
• W2895910368 creator A5054667186 @default.
• W2895910368 creator A5054858957 @default.
• W2895910368 creator A5058962433 @default.
• W2895910368 creator A5063438724 @default.
• W2895910368 creator A5064939409 @default.
• W2895910368 creator A5089013920 @default.
• W2895910368 date "2018-12-01" @default.
• W2895910368 modified "2023-10-10" @default.
• W2895910368 title "Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study" @default.
• W2895910368 cites W1998589707 @default.
• W2895910368 cites W1999653427 @default.
• W2895910368 cites W2012473911 @default.
• W2895910368 cites W2018083981 @default.
• W2895910368 cites W2052422622 @default.
• W2895910368 cites W2056981303 @default.
• W2895910368 cites W2090264937 @default.
• W2895910368 cites W2133488722 @default.
• W2895910368 cites W2146344189 @default.
• W2895910368 cites W2154326381 @default.
• W2895910368 cites W2154844490 @default.
• W2895910368 cites W2168358002 @default.
• W2895910368 cites W2170215274 @default.
• W2895910368 cites W2264219219 @default.
• W2895910368 cites W2342111708 @default.
• W2895910368 cites W2523414064 @default.
• W2895910368 cites W2550988438 @default.
• W2895910368 cites W2563618625 @default.
• W2895910368 cites W2566396342 @default.
• W2895910368 cites W2575722488 @default.
• W2895910368 cites W2576072275 @default.
• W2895910368 cites W2590583402 @default.
• W2895910368 cites W2753668595 @default.
• W2895910368 cites W2755491887 @default.
• W2895910368 cites W2783758534 @default.
• W2895910368 cites W2791308452 @default.
• W2895910368 cites W2795383053 @default.
• W2895910368 cites W2799717110 @default.
• W2895910368 doi "https://doi.org/10.1016/s1473-3099(18)30496-1" @default.
• W2895910368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30342828" @default.
• W2895910368 hasPublicationYear "2018" @default.
• W2895910368 type Work @default.
• W2895910368 sameAs 2895910368 @default.
• W2895910368 citedByCount "92" @default.
• W2895910368 countsByYear W28959103682018 @default.
• W2895910368 countsByYear W28959103682019 @default.
• W2895910368 countsByYear W28959103682020 @default.
• W2895910368 countsByYear W28959103682021 @default.
• W2895910368 countsByYear W28959103682022 @default.
• W2895910368 countsByYear W28959103682023 @default.
• W2895910368 crossrefType "journal-article" @default.
• W2895910368 hasAuthorship W2895910368A5002144784 @default.
• W2895910368 hasAuthorship W2895910368A5003579713 @default.
• W2895910368 hasAuthorship W2895910368A5004943027 @default.
• W2895910368 hasAuthorship W2895910368A5006354562 @default.
• W2895910368 hasAuthorship W2895910368A5006714387 @default.
• W2895910368 hasAuthorship W2895910368A5010157321 @default.
• W2895910368 hasAuthorship W2895910368A5014425130 @default.
• W2895910368 hasAuthorship W2895910368A5035684618 @default.
• W2895910368 hasAuthorship W2895910368A5044411310 @default.
• W2895910368 hasAuthorship W2895910368A5050887592 @default.
• W2895910368 hasAuthorship W2895910368A5054000066 @default.
• W2895910368 hasAuthorship W2895910368A5054459990 @default.
• W2895910368 hasAuthorship W2895910368A5054667186 @default.
• W2895910368 hasAuthorship W2895910368A5054858957 @default.
• W2895910368 hasAuthorship W2895910368A5058962433 @default.
• W2895910368 hasAuthorship W2895910368A5063438724 @default.
• W2895910368 hasAuthorship W2895910368A5064939409 @default.
• W2895910368 hasAuthorship W2895910368A5089013920 @default.
• W2895910368 hasConcept C104317684 @default.
• W2895910368 hasConcept C114851261 @default.
• W2895910368 hasConcept C135763542 @default.
• W2895910368 hasConcept C142724271 @default.
• W2895910368 hasConcept C159047783 @default.
• W2895910368 hasConcept C2776967927 @default.
• W2895910368 hasConcept C2777975735 @default.
• W2895910368 hasConcept C2778340795 @default.
• W2895910368 hasConcept C2778607973 @default.
• W2895910368 hasConcept C2781069245 @default.
• W2895910368 hasConcept C51679486 @default.
• W2895910368 hasConcept C54355233 @default.
• W2895910368 hasConcept C71924100 @default.
• W2895910368 hasConcept C76818968 @default.
• W2895910368 hasConcept C77434933 @default.
• W2895910368 hasConcept C86803240 @default.

• next